ProCE Banner Activity

ATEZO-BRAIN: Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases

Slideset Download
Conference Coverage
In this phase II study, atezolizumab plus carboplatin/pemetrexed was well tolerated and showed concordant systemic and intracranial efficacy in patients with advanced NSCLC and untreated brain metastases.

Released: September 20, 2021

Expiration: September 19, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme